Drugmakers Call on FDA to Clarify Biosimilar Statistical Approaches Guidance

Drug Industry Daily
A A
Genentech and Pfizer urged the FDA in written comments to make its draft guidance on statistical analyses of analytical similarity data for biosimilars more specific and narrower in scope.

To View This Article:

Login

Subscribe To Drug Industry Daily